Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.356 - [histone H3]-lysine27 N-trimethyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma of Lung
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Biliary Tract Neoplasms
3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Brain Neoplasms
Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours.
[Epigenetic analyses of brain tumor stem cells]
Breast Neoplasms
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
AMPK lifts the PRC2-implemented gene repression.
EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
EZH2 inhibition sensitizes tamoxifen?resistant breast cancer cells through cell cycle regulation.
Gene set-based module discovery in the breast cancer transcriptome.
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
MiR-101-3p and Syn-Cal14.1a Synergy in Suppressing EZH2-Induced Progression of Breast Cancer.
Carcinogenesis
An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting.
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.
EZH2 inhibition sensitizes tamoxifen?resistant breast cancer cells through cell cycle regulation.
EZH2 is a potential prognostic predictor of glioma.
EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
HIFI-? activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Long non-coding RNA functions in lung cancer.
microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma.
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Overexpression of suppressor of zest 12 is associated with cervical node metastasis and unfavorable prognosis in tongue squamous cell carcinoma.
Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-wild-type Diffuse Astrocytic Gliomas.
SUZ12 depletion suppresses the proliferation of gastric cancer cells.
SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma.
The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Carcinoma
Altered Histone Mark Deposition and DNA Methylation at Homeobox Genes in Human Oral Squamous Cell Carcinoma Cells.
Epigenetic dysregulation of key developmental genes in radiation-induced rat mammary carcinomas.
Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Impact of human MLL/COMPASS and polycomb complexes on the DNA methylome.
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
[DZNep raises miR-200c expression to delay the invasion and migration of MGC-803 gastric carcinoma cells].
Carcinoma, Hepatocellular
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway.
Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma.
Carcinoma, Non-Small-Cell Lung
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
Carcinoma, Renal Cell
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Altered Histone Mark Deposition and DNA Methylation at Homeobox Genes in Human Oral Squamous Cell Carcinoma Cells.
Chagas Disease
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
Cholangiocarcinoma
Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Colonic Neoplasms
Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
Colorectal Neoplasms
Deregulated expression of microRNA-200b/c and SUZ12, a Polycomb repressive complex 2 subunit, in chemoresistant colorectal cancer cells.
EZH2 inhibition promotes methyl jasmonate-induced apoptosis of human colorectal cancer through the Wnt/?-catenin pathway.
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Diabetic Cardiomyopathies
ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications.
Diabetic Nephropathies
ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications.
[EZH2 promotes development and progression of diabetic nephropathy].
Diabetic Retinopathy
Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy.
Encephalomyelitis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Encephalomyelitis, Autoimmune, Experimental
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Endometriosis
Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.
Ependymoma
EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Esophageal Squamous Cell Carcinoma
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
Glioblastoma
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Glioma
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner.
Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.
Hematologic Neoplasms
Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation.
Hepatitis B
EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes.
Huntington Disease
Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation.
Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.
Infections
Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells.
Polycomb Repressive Complex 2 Silences Human Cytomegalovirus Transcription in Quiescent Infection Models.
Viral-encoded enzymes that target host chromatin functions.
Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle.
Influenza, Human
Polycomb repressive complex 2 facilitates the nuclear export of the influenza viral genome through the interaction with M1.
Kidney Neoplasms
Epigenetic Marks Repressing Gluconeogenesis in Liver and Kidney Cancer.
Leukemia
Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis.
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Leukemia, Myeloid, Acute
Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.
Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.
Liver Neoplasms
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer.
Lung Diseases
Ezh2 controls development of natural killer T cells, which cause spontaneous asthma-like pathology.
Lung Neoplasms
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.
Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-?-Smad-ASCL1 pathway.
Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer.
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression.
Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.
Lymphatic Metastasis
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.
Lymphoma
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.
Polycomb repressive complex 2 (PRC2) suppresses E?-myc lymphoma.
Lymphoma, B-Cell
Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
Lymphoma, Large B-Cell, Diffuse
Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
Lymphoma, T-Cell
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.
Lymphoma, T-Cell, Cutaneous
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.
Medulloblastoma
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Melanoma
Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk.
EZH2 as a mediator of treatment resistance in melanoma.
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.
Mesothelioma
Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
Mesothelioma, Malignant
Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
Multiple Myeloma
Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
Multiple Sclerosis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Myelodysplastic Syndromes
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.
Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
Neoplasm Metastasis
Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.
Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma.
Neoplasms
3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.
Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors.
Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis.
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways.
Characterization of the expression pattern of the PRC2 core subunit Suz12 during embryonic development of Xenopus laevis.
Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Coordinated Regulation of Retinoic Acid Signaling Pathway by KDM5B and Polycomb Repressive Complex 2.
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer.
Differential Expression of EZH2 and H3K27me3 in Oral Verrucous Carcinoma and Oral Verrucous Hyperplasia.
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma.
DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment.
Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
EED inhibition suppresses cancers by modulating the immune response.
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.
ENHANCER OF ZESTE 2 (EZH2) IS UP-REGULATED IN MALIGNANT GLIOMAS AND IN GLIOMA STEM-LIKE CELLS.
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.
Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma.
Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Epigenetic Marks Repressing Gluconeogenesis in Liver and Kidney Cancer.
Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.
Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
EZH2 enhances the invasive capability of renal cell carcinoma cells via activation of STAT3.
EZH2 expression in invasive lobular carcinoma of the breast.
EZH2 inhibition sensitizes tamoxifen?resistant breast cancer cells through cell cycle regulation.
EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
EZH2 is a potential prognostic predictor of glioma.
EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer.
EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
EZH2: novel therapeutic target for human cancer.
First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.
G-tract RNA removes Polycomb repressive complex 2 from genes.
Gene set-based module discovery in the breast cancer transcriptome.
Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs.
H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells.
Hhex Regulates Hematopoietic Stem Cell Self-Renewal and Stress Hematopoiesis via Repression of Cdkn2a.
HIFI-? activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.
Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.
Identification of a Chemical Modulator of EZH2-mediated Silencing by Cell-based High-throughput Screening Assay.
Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
JAK2 regulates mismatch repair protein-mediated epigenetic alterations in response to oxidative damage.
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.
Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma.
Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.
MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10.
MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity.
miR-367 as a therapeutic target in stem-like cells from embryonal central nervous system tumors.
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
MUC1-C activates EZH2 expression and function in human cancer cells.
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-wild-type Diffuse Astrocytic Gliomas.
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Polycomb group proteins in cell cycle progression and cancer.
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Polycomb Repressive Complex 2 Enacts Wnt Signaling in Intestinal Homeostasis and Contributes to the Instigation of Stemness in Diseases Entailing Epithelial Hyperplasia or Neoplasia.
Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner.
Polycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewal.
Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
PRC2 is dispensable for HOTAIR-mediated transcriptional repression.
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep).
Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis.
Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
Promiscuous RNA binding by Polycomb repressive complex 2.
Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines.
Proteomic analyses identify a novel role for EZH2 in the initiation of cancer cell drug tolerance.
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Response to Comment on "Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2".
Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.
Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
SUMOylation of E2F1 Regulates Expression of EZH2.
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
The Multiple Facets of PRC2 Alterations in Cancers.
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.
The role of ASXL1 in hematopoiesis and myeloid malignancies.
Towards understanding of PRC2 binding to RNA.
TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep).
Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
Neoplasms, Germ Cell and Embryonal
Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.
Neuralgia
EZH2 regulates spinal neuroinflammation in rats with neuropathic pain.
Neuroblastoma
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Origin and initiation mechanisms of neuroblastoma.
Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma: FUNCTIONAL AND THERAPEUTIC IMPLICATIONS.
Neurodegenerative Diseases
Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.
Neurofibrosarcoma
A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
Malignant Peripheral Nerve Sheath Tumors Show Decreased Global DNA Methylation.
Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
[Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Osteosarcoma
Decreased long non-coding RNA lincFOXF1 indicates poor progression and promotes cell migration and metastasis in osteosarcoma.
Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.
Ovarian Neoplasms
EZH2-miRNA Positive Feedback Promotes Tumor Growth in Ovarian Cancer.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
The role of polycomb repressive complex 2 in early T-cell precursor acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.
Primary Myelofibrosis
Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.
Prostatic Neoplasms
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Retinoblastoma
Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.
Dosage-sensitive function of retinoblastoma related and convergent epigenetic control are required during the Arabidopsis life cycle.
Rbbp4 suppresses premature differentiation of embryonic stem cells.
Rett Syndrome
CAGE-defined promoter regions of the genes implicated in Rett Syndrome.
Sarcoma
CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.
Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
Sarcoma, Endometrial Stromal
CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.
Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
Seizures
Inhibition of EZH2 attenuates inhibitory synaptic transmission via the pro-inflammatory pathway in rats.
Skin Neoplasms
Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk.
Small Cell Lung Carcinoma
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-?-Smad-ASCL1 pathway.
Squamous Cell Carcinoma of Head and Neck
Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.
Stomach Neoplasms
Long noncoding RNA LINC00165-induced by STAT3 exerts oncogenic properties via interaction with Polycomb Repressive Complex 2 to promote EMT in gastric cancer.
Thyroid Neoplasms
Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.
Urinary Bladder Neoplasms
EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway.
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.
MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity.
[histone h3]-lysine27 n-trimethyltransferase deficiency
Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8(+) T Cell Terminal Differentiation and Loss of Multipotency.